LPCN Lipocine Inc
Price (delayed)
$3
Market cap
$16.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$9.85M
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN
Highlights
LPCN's net income has soared by 100% QoQ and by 100% YoY
Lipocine's EPS has surged by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of LPCN
Market
Valuations
Earnings
Shares outstanding
5.35M
Market cap
$16.05M
Enterprise value
$9.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.76
Price to sales (P/S)
1.43
EV/EBIT
1,089.91
EV/EBITDA
196.36
EV/Sales
0.88
Revenue
$11.2M
Gross profit
$11.2M
Operating income
-$1.16M
Net income
$8,352
EBIT
$9,033
EBITDA
$50,139
Free cash flow
-$1.31M
Per share
Balance sheet
Liquidity
EPS
$0
EPS diluted
$0
Free cash flow per share
-$0.25
Book value per share
$3.93
Revenue per share
$2.1
TBVPS
$4.22
Total assets
$22.51M
Total liabilities
$1.51M
Debt
$0
Equity
$21M
Working capital
$20.81M
Debt to equity
0
Current ratio
14.75
Quick ratio
14.3
Net debt/EBITDA
-123.77
Margins
Efficiency
Dividend
EBITDA margin
0.4%
Gross margin
100%
Net margin
0.1%
Operating margin
-10.3%
Return on assets
0%
Return on equity
0%
Return on invested capital
0.1%
Return on capital employed
0%
Return on sales
0.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LPCN stock price
How has the Lipocine stock price performed over time
Intraday
-0.33%
1 week
-4.46%
1 month
-14.29%
1 year
-43.61%
YTD
-38.52%
QTD
-5.66%
Financial performance
How have Lipocine's revenue and profit performed over time
Revenue
$11.2M
Gross profit
$11.2M
Operating income
-$1.16M
Net income
$8,352
Gross margin
100%
Net margin
0.1%
LPCN's net margin has surged by 100% since the previous quarter
LPCN's net income has soared by 100% QoQ and by 100% YoY
The company's operating income has surged by 94% YoY and by 78% QoQ
LPCN's operating margin has surged by 85% since the previous quarter
Growth
What is Lipocine's growth rate over time
Valuation
What is Lipocine stock price valuation
P/E
N/A
P/B
0.76
P/S
1.43
EV/EBIT
1,089.91
EV/EBITDA
196.36
EV/Sales
0.88
Lipocine's EPS has surged by 100% QoQ and by 100% YoY
The P/B is 67% less than the 5-year quarterly average of 2.3 and 45% less than the last 4 quarters average of 1.4
Lipocine's equity has increased by 10% QoQ and by 3.1% YoY
The price to sales (P/S) is 72% lower than the last 4 quarters average of 5.1
LPCN's revenue is up by 41% since the previous quarter
Efficiency
How efficient is Lipocine business performance
LPCN's ROA has soared by 100% since the previous quarter and by 100% year-on-year
Lipocine's ROE has soared by 100% from the previous quarter and by 100% YoY
Lipocine's return on sales has surged by 100% QoQ
The ROIC has soared by 100% from the previous quarter and by 100% YoY
Dividends
What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LPCN.
Financial health
How did Lipocine financials performed over time
The quick ratio has soared by 71% YoY and by 14% from the previous quarter
The current ratio has soared by 70% YoY and by 14% from the previous quarter
LPCN's debt is 100% smaller than its equity
Lipocine's equity has increased by 10% QoQ and by 3.1% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.